Home/Ovid Therapeutics/Thomas Perone
TP

Thomas Perone

Chief Legal Officer & Corporate Secretary

Ovid Therapeutics

Ovid Therapeutics Pipeline

DrugIndicationPhase
OV329Treatment-resistant seizuresPhase 1
OV350Undisclosed CNS disordersPreclinical
OV882SYNGAP1-related intellectual disabilityResearch
OV4071Undisclosed CNS disordersResearch
Soticlestat (OV935/TAK-935)Dravet Syndrome, Lennox-Gastaut SyndromePhase 3